InnoCan Pharma (TSE:INNO) has released an update.
InnoCan Pharma has reported favorable results from a preliminary safety evaluation of its LPT-CBD drug on minipigs, with no adverse effects observed, supporting its potential in sustained-release therapy. This successful animal trial marks a significant step towards the drug’s further development and possible approval. The study supports previous positive evaluations in other animals and is part of InnoCan’s ongoing efforts to revolutionize patient care with their innovative drug delivery technologies.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
